John Leonard, Intellia Therapeutics CEO
November 18, 2024 04:09 AM ESTUpdated 06:21 AM
R&D
Cell/Gene Tx

In­tel­lia touts first clin­i­cal out­comes on CRISPR-based AT­TR amy­loi­do­sis as­set

Lei Lei Wu

News Reporter

In one of the most close­ly-watched are­nas in biotech, In­tel­lia says its gene edit­ing treat­ment for a heart mus­cle dis­ease can sta­bi­lize or im­prove out­comes …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Up­dat­ed: No­vo’s 23% weight loss with Ca­griSe­ma falls short of high ex­pec­ta­tions, new tri­al planned

FDA ap­proves Hu­ma­cyte’s lab-grown blood ves­sels in mile­stone for re­gen­er­a­tive med­i­cine

Ex­clu­sive: Flori­da can­cer biotech rais­es $100M Se­ries A

Ac­cel­er­at­ed ap­proval brings Pfiz­er's BRAF in­hibitor to first-line pa­tients

FDA ap­proves Io­n­is’ treat­ment for a rare meta­bol­ic dis­or­der

A service from the Financial Times